As published in The Australian, Prof Richard Scolyer AO’s friends and colleagues, Professor Georgina Long AO and Dr Kerry Crotty, share their reflections on Richard’s extraordinary spirit, his exceptional contributions to the fields of melanoma and pathology, and his lasting legacy.
Over the next three months, Prof Georgina Long will work with some of Europe's leading cancer research and treatment centres, advancing collaborative research in melanoma and neoadjuvant immunotherapy.
All of us at Melanoma Institute Australia (MIA) and the wider melanoma community are mourning the loss of our esteemed colleague and friend, Professor Richard Scolyer AO.
A World Health Organisation global study published in the Nature Medicine journal showed that 2 in every 5 cancers could be prevented. It found that in Australia the leading risk factor for preventable cancers in men is exposure to UV radiation.
Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
